Melinta Therapeutics Quick Ratio (CEMP) starting from the third quarter 2019 to third quarter 2018, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Melinta Therapeutics, Inc.  (CEMP)

Melinta Therapeutics's Quick Ratio

CEMP's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Regardless of the sequential decrease in Current Liabilities, during the third quarter 2019, Quick Ratio deteriorated to 0.5 a new company low.

Within Major Pharmaceutical Preparations industry 435 other companies have achieved higher Quick Ratio than Melinta Therapeutics in third quarter 2019. While Quick Ratio total ranking in the third quarter 2019 has deteriorated compared to the prior quarter from 2157 to 2575.

Explain Quick Ratio?
How much Cash & cash equivalents CEMP´s has?
What are CEMP´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

CEMP Quick Ratio (Sep 30 2019)
Q3		 (Jun 30 2019)
Q2		 (Mar 31 2019)
Q1		 (Dec 31 2018)
Q4		 (Sep 30 2018)
Q3
Y / Y Current Liabilities Change 3.55 % 23.85 % 210.17 % 321.07 % 689.95 %
Y / Y Cash & cash equivalent Change -24.19 % -39.81 % 27.79 % -36.28 % -52.43 %
Quick Ratio MRQ 0.5 0.68 0.9 0.61 0.68
CEMP's Total Ranking # 2575 # 2157 # 2516 # 2263 # 2503
Seq. Current Liabilities Change -3.28 % 1.87 % -2.73 % 8.04 % 15.68 %
Seq. Cash & cash equivalent Change -29.69 % -22.72 % 42.9 % -2.37 % -44.17 %



Quick Ratio third quarter 2019 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 436
Healthcare Sector # 764
Overall Market # 2575


Quick Ratio Statistics
High Average Low
30.16 8.5 0.5
(Jun 30 2013)   (Sep 30 2019)




Financial Statements
Melinta Therapeutics's Current Liabilities $ 128 Millions Visit CEMP's Balance sheet
Melinta Therapeutics's Cash & cash equivalent $ 64 Millions Visit CEMP's Balance sheet
Source of CEMP's Sales Visit CEMP's Sales by Geography


Cumulative Melinta Therapeutics's Quick Ratio

CEMP's Quick Ratio for the trailling 12 Months

CEMP Quick Ratio

 (Sep 30 2019)
12 Months		 (Jun 30 2019)
12 Months		 (Mar 31 2019)
12 Months		 (Dec 31 2018)
12 Months		 (Sep 30 2018)
12 Months
Y / Y Current Liabilities TTM Growth 72.26 % 164.87 % 370.16 % 367.3 % 291.31 %
Y / Y Cash & cash equivalent TTM Growth -22.3 % -31.72 % -25.8 % -41.35 % -21.4 %
Quick Ratio TTM 0.67 0.72 0.88 1 1.49
Total Ranking TTM # 5017 # 619 # 1813 # 1808 # 4676
Seq. Current Liabilities TTM Growth 0.84 % 5.16 % 21.69 % 33.49 % 55.05 %
Seq. Cash & cash equivalent TTM Growth -5.44 % -13.81 % 6.24 % -10.27 % -16.91 %

Quick ratio ranking by company, industry and sector >> Back to CEMP Financial Strength Comparisons >> Go to Compare CEMP Quick Ratio to its Competitors

On the trailing twelve months basis Due to decrease in Current Liabilities in the Q3 2019 to $128.05 millions, cumulative Quick Ratio decreased to 0.67 below the Melinta Therapeutics, Inc. average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 468 other companies have achieved higher Quick Ratio than Melinta Therapeutics. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2019 from 619 to 5017.

Explain Quick Ratio?
How much Cash & cash equivalents CEMP´s has?
What are CEMP´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 469
Healthcare Sector # 924
Within the Market # 5017


trailing twelve months Quick Ratio Statistics
High Average Low
14.04 6.96 0.67
(Dec 31 2013)   (Sep 30 2019)




Companies with similar Quick Ratio in the quarter ending Sep 30 2019, within Major Pharmaceutical Preparations Industry Quick RatioSep 30 2019 MRQ Cash & cash equivalentSep 30 2019 MRQ Current Liabilities
Bellicum Pharmaceuticals Inc   1.35 $ 103.303  Millions$ 76.438  Millions
Forte Biosciences Inc   1.33 $ 55.342  Millions$ 41.746  Millions
Kamada Ltd   1.30 $ 42.662  Millions$ 32.739  Millions
Serina Therapeutics Inc   1.30 $ 3.768  Millions$ 2.907  Millions
Puma Biotechnology Inc   1.29 $ 110.439  Millions$ 85.827  Millions
Sio Gene Therapies Inc   1.28 $ 60.300  Millions$ 47.279  Millions
Cypherpunk Technologies Inc   1.27 $ 10.058  Millions$ 7.931  Millions
Vaccinex Inc   1.24 $ 8.578  Millions$ 6.896  Millions
Biodexa Pharmaceuticals Plc  1.24 $ 16.911  Millions$ 13.615  Millions
Purple Biotech Ltd  1.24 $ 4.385  Millions$ 3.546  Millions
Kadmon holdings inc   1.22 $ 66.132  Millions$ 54.324  Millions
Biodelivery Sciences International Inc   1.20 $ 55.863  Millions$ 46.545  Millions
Kiora Pharmaceuticals Inc   1.20 $ 2.455  Millions$ 2.050  Millions
Cv Sciences Inc   1.20 $ 13.738  Millions$ 11.476  Millions
Soligenix inc   1.19 $ 6.552  Millions$ 5.493  Millions
Procyon Corporation  1.19 $ 0.443  Millions$ 0.372  Millions
Athenex Inc   1.19 $ 103.754  Millions$ 87.158  Millions
Amphastar Pharmaceuticals Inc   1.16 $ 100.567  Millions$ 86.596  Millions
Aytu Biopharma Inc  1.15 $ 7.014  Millions$ 6.102  Millions
Emmaus Life Sciences Inc   1.13 $ 28.969  Millions$ 25.709  Millions
Dmk Pharmaceuticals Corporation  1.12 $ 12.122  Millions$ 10.835  Millions
Medicure Inc   1.11 $ 9.931  Millions$ 8.933  Millions
Oncolytics Biotech Inc   1.10 $ 10.837  Millions$ 9.858  Millions
Trillium Therapeutics Inc   1.08 $ 14.584  Millions$ 13.527  Millions
Camp4 Therapeutics Corporation  1.07 $ 201.473  Millions$ 189.105  Millions
Endo International Plc  1.05 $ 1,748.741  Millions$ 1,667.727  Millions
Avid Bioservices Inc   1.01 $ 33.960  Millions$ 33.672  Millions
Vbi Vaccines Inc  1.00 $ 53.016  Millions$ 53.014  Millions
Vistagen Therapeutics Inc   0.99 $ 4.072  Millions$ 4.117  Millions
Amag Pharmaceuticals inc   0.94 $ 191.544  Millions$ 204.074  Millions

Date modified: 2026-09-26T06:56:48+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.